A Phase 1/2 interventional study of pentostatin for injection in Acute Graft Versus Host Disease, sponsored by Astex Pharmaceuticals, Inc.. Terminated at 1 site in United States. Open to participants aged 6 Months and older. Per ClinicalTrials.gov, last updated 2024-08-02.
Sponsored by Astex Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment
To determine a safe and effective dose of pentostatin in steroid-refractory aGvHD and to identify the minimal effective dose of pentostatin defined as the lowest dose that produces a response in 20% or more of patients while producing treatment failure (defines as death, grade 3/4 toxicity, or progressive disease) in 40% or less of patients.
806 studies on the registry are indexed under Graft vs Host Disease; 138 are open to participants now.
This study's enrollment of 36 is close to the median of 35 across 637 interventional studies indexed under Graft vs Host Disease.
Browse Graft vs Host Disease studies →Astex Pharmaceuticals, Inc. is the lead sponsor of 42 studies on the registry; none are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 6 (46%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion:
This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Astex Pharmaceuticals, Inc.